LNP formulations produce strong immune responses, data shows
Drug Discovery World
FEBRUARY 15, 2024
Hypothetically, any mRNA-based drug using S-Ac7-DOG as the lipid base would therefore have improved efficacy and a better safety profile.
‘Proactive’ vaccine can protect against unknown future coronaviruses
Drug Discovery World
MAY 15, 2024
Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. By training the immune system to attack these regions, it gives protection against other coronaviruses not represented in the vaccine.
Vaccine 
130
130 Join 42,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Study proves value of infection studies in developing new vaccines
Drug Discovery World
MAY 2, 2024
A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The results suggest that previous infection, together with vaccination, offers strong protection against the original Covid-19 strain.
Vaccine 147
147 
Clinical trial will test novel inhaled TB vaccine
Drug Discovery World
JANUARY 16, 2024
A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin. The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB.
Clinical Trials 147
147 
Vaccines and various response rates
Drug Discovery World
MAY 30, 2024
DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. KP: Our immune system changes across different life stages.
Vaccine 147
147 
Positive initial results for srRNA rabies vaccine
Drug Discovery World
FEBRUARY 19, 2024
Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).
Vaccine 130
130 
Ginkgo Bioworks to discover and develop novel vaccine adjuvants
Drug Discovery World
FEBRUARY 20, 2024
A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The post Ginkgo Bioworks to discover and develop novel vaccine adjuvants appeared first on Drug Discovery World (DDW).
Vaccine 130
130 
Bimervax Covid-19 vaccine authorised in UK
Drug Discovery World
AUGUST 3, 2023
It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. The clinical evidence for the authorisation is based on data from a study of 765 adults who had received primary vaccination with two doses of the Comirnaty Covid-19 vaccine and who were given a booster dose of either Bimervax or Comirnaty.
Vaccine 130
130 
“Game-changing” personalised cancer vaccine enters UK clinical trials
Drug Discovery World
APRIL 26, 2024
A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. in the combination arm and 62.2%
Clinical Trials 130
130 
AI tool predicts new viral variants and could improve vaccines
Drug Discovery World
OCTOBER 13, 2023
The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).
Vaccine 264
264 
Chlamydia Vaccine Shows Promise in Early Trial
Drugs.com
APRIL 12, 2024
FRIDAY, April 12, 2024 -- A chlamydia vaccine has triggered immune responses in an early trial, raising hopes that one day it might help curb the spread of the sexually transmitted infection (STI).There There is currently no vaccine for chlamydia, which.
Vaccine 114
114 
Phase I trial of next-generation srRNA rabies vaccine
Drug Discovery World
SEPTEMBER 15, 2023
Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Replicate’s srRNA technology offers the potential for more robust and durable immune responses, and improved tolerability at lower doses than existing mRNA approaches,” said Zelanna Goldberg, CMO of Replicate. “In
Vaccine 130
130 
Chinese regulator approves personalised cancer vaccine trial
Drug Discovery World
MARCH 30, 2023
Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.
Vaccine 130
130 
mRNA universal influenza vaccine enters clinical trials
Drug Discovery World
MAY 18, 2023
A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.
Clinical Trials 130
130 
Nanoparticle universal flu vaccine enters Phase I trials
Drug Discovery World
SEPTEMBER 25, 2023
Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus. “An
Vaccine 130
130 
Oxford study to allow tailoring of Covid-19 and flu vaccines
Drug Discovery World
OCTOBER 31, 2023
The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. As we age, our immune system changes and with it our response to vaccines.
Vaccine 130
130 
Microarray patches safe and effective for vaccinating children, trial suggests
Science Daily: Pharmacology News
APRIL 29, 2024
The first study of the use of microarray patches to vaccinate children has shown that the method is safe and induces strong immune responses.
Vaccine 103
103 
Personalised mRNA cancer vaccine prolongs survival in melanoma
Drug Discovery World
APRIL 16, 2023
Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%
Vaccine 130
130 
AstraZeneca’s Vaccine Produced Immune Responses in Older Patients
The Pharma Data
OCTOBER 26, 2020
AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Source link.
Preclinical data supports arenaviral therapeutic vaccine for hepatitis B
Drug Discovery World
OCTOBER 27, 2023
HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.
Vaccine 130
130 
Clamp2 provides vaccine hope for future pandemics
Drug Discovery World
NOVEMBER 30, 2022
The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Image: Dr Noushin Jaberolansar and Dr Andrew Young at lab bench.
Vaccine 130
130 
Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
The Pharma Data
DECEMBER 4, 2021
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).
Routine vaccines as effective as antibodies against Alzheimer’s
Drug Discovery World
AUGUST 25, 2023
A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). In 2022, Schulz’s team also found that people who received at least one influenza vaccine were 40% less likely than their unvaccinated peers to develop AD.
Vaccine 130
130 
AstraZeneca’s COVID-19 Vaccine Delivers Strong Immune Response, Study Confirms
The Pharma Data
OCTOBER 22, 2020
AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Source link.
New Covid-19 booster outperforms approved vaccines
Drug Discovery World
FEBRUARY 23, 2023
Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP). 5 variants compared to adenovirus vector (ChAdOx1-S) and inactivated (BIBP) vaccines.
Vaccine 130
130 
Plant-based squalene alternative suitable for vaccine use
Drug Discovery World
DECEMBER 8, 2022
Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. Adjuvants are additives that boost the body’s immune response to the active ingredient in a vaccine. Squalene is a natural organic compound that is used as a component in some adjuvant systems.
Vaccine 130
130 
Experimental cancer vaccine shows promise in animal studies
Drug Discovery World
NOVEMBER 15, 2022
An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .
Vaccine 130
130 
Study insights may aid TB vaccine development
Drug Discovery World
NOVEMBER 4, 2022
New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. The identification of specific correlates of protection for infection could support the development of a vaccine against M.tb
Vaccine 130
130 
LDL cholesterol vaccine ‘could be a game-changer’
Drug Discovery World
MARCH 27, 2023
The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. With an LDL-lowering vaccine we can potentially offer an option that’s cost-effective, safe, convenient, long-acting, and deployable.”
Vaccine 130
130 
Advancing vaccine design: potential of peptide mimicry
Drug Target Review
AUGUST 11, 2023
In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The implications of this finding are far-reaching, as it holds the potential to revolutionize vaccine design.
Vaccine 98
98 
Breakthrough Therapy designation for pneumococcal disease vaccine
Drug Discovery World
JANUARY 10, 2023
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. . The post Breakthrough Therapy designation for pneumococcal disease vaccine appeared first on Drug Discovery World (DDW).
Vaccine 130
130 
A COVID Vaccine-by-Mouth Could Be on the Way
Drugs.com
SEPTEMBER 14, 2023
14, 2023 -- An oral vaccine for COVID-19 appears to produce the sort of immune response that could quickly stamp out a developing infection, according to results from a small-scale primate study. THURSDAY, Sept. Some monkeys given an experimental.
Vaccine 118
118 
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
The Pharma Data
AUGUST 16, 2021
The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.
Nasal Spray COVID Vaccine Shows Promise in Early Trial
Drugs.com
OCTOBER 11, 2023
11, 2023 -- New research points to the potential of a COVID-19 vaccine delivered through the nose. The phase 1 clinical trial showed that the product, administered nasally in two doses, delivered a significant immune response to. WEDNESDAY, Oct.
Vaccine 96
96 
Merck and Moderna to jointly develop personalised cancer vaccine
Drug Discovery World
NOVEMBER 8, 2022
Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).
Vaccine 130
130 
HIV combination regimen could lead to viral remission
Drug Discovery World
FEBRUARY 24, 2023
AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The trial also evaluated the efficacy of HTI vaccines in combination with VES to avoid, delay or contain viral rebound compared to a placebo group.
Immune Response 130
130 
Pfizer-BioNTech reports strong immune response in animals to its COVID-19 vaccine
The Pharma Data
SEPTEMBER 10, 2020
Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Tareq Aziz Touhid. The study and the data are currently subject to peer review.
Engineers design more powerful RNA vaccines
Science Daily: Pharmacology News
SEPTEMBER 7, 2023
By adding synergistic self-adjuvanting properties to Covid-19 RNA vaccines, researchers showed they could significantly boost the immune response generated in mice.
RNA 80
80 
Medicago Says COVID-19 Vaccine Candidate Triggers Promising Immune Response | 2020-11-10
The Pharma Data
NOVEMBER 10, 2020
Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. microgram or 15-microgram doses of the vaccine candidate, either alone or with an adjuvant.
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine
Drug Discovery Today
APRIL 15, 2021
First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial the vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit). 176 volunteers will participate in the clinical trial the safety and immune response read-outs expected in Q2 2021
Clinical Trials 113
113 
MHRA approves Moderna’s bivalent Covid booster
Drug Discovery World
AUGUST 16, 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s Covid-19 booster vaccine that targets two coronavirus variants. . Known as a bivalent vaccine, Spikevax was approved following data that show it triggers a strong immune response against both Omicron (BA.1)
Immune Response 130
130 
A chance to design better vaccines?
SCIENMAG: Medicine & Health
JULY 24, 2023
A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.
Vaccine 60
60 
Could a modified cold sore virus cure brain cancer?
Drug Discovery World
MAY 23, 2024
A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The virus also increased the number of immunity-boosting white blood cells within the tumours. million of funding for this research project.
Virus 147
147 
Covid-19 causes long-term damage to the immune system
Drug Discovery World
MARCH 23, 2023
The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. Taken together, these findings suggest that SARS-CoV-2 infection damages the CD8+ T cell response.
Immune Response 130
130 
Let's personalize your content